Compound overviews
3 min read Last updated March 7, 2026By PrimeGen Research TeamBeginner
Two peptides that appear together in most tissue-repair research preparations, with different sequences, different reported mechanisms, and different handling characteristics. A side-by-side comparison.
Two peptides that appear together in most tissue-repair research preparations, with different sequences, different reported mechanisms, and different handling characteristics. A side-by-side comparison. This guide is published by PrimeGen Co., a United States supplier of lyophilized research peptides, and covers compound overviews for laboratory research contexts only.
BPC-157 is a fifteen-residue synthetic peptide (GEPPPGKPADDAGLV) described as a partial sequence of body protection compound found in gastric juice, molecular weight approximately 1419 Da.
TB-500 is a synthetic seven-residue fragment corresponding to the actin-binding region of thymosin beta-4, molecular weight approximately 889 Da. It is not thymosin beta-4 itself, which is a 43-residue protein — a naming distinction that matters when reading literature.
The BPC-157 literature centres on angiogenic signalling through the VEGFR2-Akt-eNOS axis, nitric oxide system modulation, and growth hormone receptor expression in fibroblast models, with a large rodent gastrointestinal cytoprotection body of work.
The TB-500 literature centres on actin sequestration and cell migration: the fragment binds G-actin, and the reported effects concern cytoskeletal remodelling, keratinocyte and endothelial migration, and downregulation of inflammatory signalling in injury models.
The two act on largely non-overlapping pathways — angiogenesis and vascular signalling on one side, actin-driven cell migration on the other — which is the stated rationale for the combination preparations that appear across the tissue-repair literature.
In a study design, the combination only produces interpretable data when single-agent arms are run alongside it. Combining two compounds without controls makes any observed effect impossible to attribute.
Both are stored lyophilized at -20°C protected from light and reconstitute readily in neutral aqueous diluent without acid assistance. BPC-157 is notably acid stable relative to comparable short peptides; TB-500 is a smaller, highly soluble fragment.
Both are supplied for laboratory research use only, each against an independent purity report for the specific lot.
BPC-157 is a 15-residue synthetic sequence derived from a fragment of a gastric protein; TB-500 is a fragment of the 43-residue actin-sequestering peptide thymosin beta-4. They share a literature niche and almost nothing else. Their sequences are unrelated, their proposed mechanisms in published preclinical work are unrelated, and their analytical profiles differ enough that the same method is not necessarily optimal for both.
The most consequential practical difference is stability. BPC-157 is frequently described as unusually robust for a peptide of its size, which is part of why it is so widely studied; the thymosin fragment is highly hydrophilic and correspondingly more moisture-sensitive as a lyophilized solid. Neither property transfers to the other.
Comparisons between them in secondary sources are therefore usually comparisons of research areas rather than of molecules. Where a comparison is needed for documentation purposes, the defensible axes are sequence, molecular weight, solubility behaviour, and what a complete certificate should report for each — not relative effectiveness, which no research-use context supports.
For BPC-157, the analytically interesting features are its small size, which makes deletion-sequence impurities well resolved on a standard gradient, and the absence of cysteine, which removes disulfide scrambling from the list of concerns. Mass confirmation against the 15-residue theoretical mass is straightforward.
For the thymosin fragment, the analytically interesting feature is hydrophilicity, which affects retention and can compress the separation between the target and close relatives on a poorly chosen gradient. The lack of tryptophan also removes 280-nanometre quantitation as an option.
Blend products containing both are common in the research supply and add a third documentation requirement: the certificate must characterise each component separately and state the ratio, because a single purity figure for a two-component blend is not interpretable.
The two compounds are grouped by research area rather than by chemistry. These are the axes on which they genuinely differ.
| Property | BPC-157 | TB-500 (thymosin beta-4 fragment) |
|---|---|---|
| Parent origin | Fragment derived from a gastric protein | Fragment of thymosin beta-4 (43 residues) |
| Approximate length | 15 residues | Short actin-binding fragment |
| Cysteine present | No — no disulfide scrambling | No — no disulfide scrambling |
| Tryptophan present | No — 280 nm quantitation unreliable | No — 280 nm quantitation unreliable |
| Aqueous solubility | Readily soluble | Highly hydrophilic, readily soluble |
| Chromatographic behaviour | Well-resolved deletion impurities on a standard gradient | Early retention; close relatives can compress on a steep gradient |
| Certificate priority | Mass confirmation against 15-residue theoretical mass | Mass confirmation identifying which form was made |
Relative effectiveness is deliberately excluded — no research-use context supports that comparison.
Compounds covered by this article, each with its own monograph, specifications and lot-specific certificate of analysis.
Independent, lot-specific analysis for the compounds covered above. Every report is indexed in the certificate library.
PrimeGen Research Team
Analytical & technical writing, PrimeGen Co.
Our library is written in-house by the same team that reviews incoming lot analytics, reads third-party certificates of analysis and maintains compound documentation. Articles are educational reference material for laboratory professionals and describe published in vitro and preclinical literature only.
Published August 3, 2025 · Last reviewed March 7, 2026
This page is editorial reference material published by PrimeGen Co.. It is not a peer-reviewed publication and carries no DOI; cite it as a web resource.
PrimeGen Co.. "BPC-157 vs TB-500: how the two differ." PrimeGen Co. research documentation. Last updated March 7, 2026. https://primegenco.com/library/bpc-157-vs-tb-500
Each hub sequences the guides, quality documentation and bench notes for a single topic, so you can move from this page into a structured reading path rather than a flat index.
For laboratory research purposes only. Not intended for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. Purchasers are responsible for complying with all applicable laws and regulations.
The natural continuation of this article — each piece builds on what you have just read rather than repeating it.
Trust & quality
Documentation, analytical methodology and handling practice referenced throughout the research library.
Explore further
Move from this article into the catalog, the analytical documentation behind each lot, and the policies that govern every order.